• Clint Taonaishe Chimbangu, Li Xi, Zhou Ya, Zhao Jiayue, Meng Xiao, Wang Ying, Yu Xingxu, and Xiaomei Liu.
• Jinzhou Medical University, Liaoning, Jinzhou, China.
• Medicine (Baltimore). 2024 Feb 23; 103 (8): e34654e34654.

BackgroundThe research on the relationship between the Braf Proto-oncogene (BRAF) mutation and lung cancer has generated conflicting findings. Nevertheless, there is an argument suggesting that assessing the BRAF status could offer benefits in terms of managing and prognosing individuals with non-small cell lung cancer (NSCLC). To present a comprehensive overview of this subject, we undertook an up-to-date meta-analysis of pertinent publications.MethodsWe conducted an extensive literature search utilizing Medical Subject Headings keywords, namely "BRAF", "mutation", "lung", "tumor", "NSCLC", and "neoplasm", across multiple databases, including PubMed, EMBASE, ISI Science Citation Index, and CNKI. For each study, we calculated and evaluated the odds ratio and confidence interval, focusing on the consistency of the eligible research.ResultsThe meta-analysis unveiled a noteworthy correlation between BRAF mutation and lung cancer. No significant evidence was found regarding the connection between smoking and staging among individuals with BRAF mutations. Furthermore, a substantial disparity in the rate of BRAF mutations was observed between males and females.ConclusionOur meta-analysis revealed a significant correlation between BRAF mutations and NSCLC. Moreover, we observed a higher incidence of BRAF lung mutations in females compared to males. Additionally, the BRAFV600E mutation was found to be more prevalent among female patients and nonsmokers.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…